There are wide variety of S&P/ASX 200 Index (ASX: XJO) share opportunities that we can buy. When one analyst thinks a business is a buy, that’s interesting. When there’s multiple brokers that think a stock is a buy, it could be a great opportunity.

Reporting season has recently finished, giving experts the chance to look over the numbers and valuations and select some of the best opportunities on the ASX.

Below are two of the most popular ASX 200 shares among analysts.

Breville Group Ltd (ASX: BRG)

Breville is one of the world’s leading coffee machine businesses, with multiple brands including Breville, Sage, Lelit and Baratza. It also has a coffee bean business called Beanz.

According to CMC Markets, there have been seven analyst ratings on the business within the last three months. All seven of those ratings were a buy. Not many ASX 200 shares have a 100% positive rating.

The average price target of those seven ratings on the ASX share is $37.36, which implies a possible rise of 18% from where it is at the time of writing. The most optimistic price target is $41.07, suggesting a possible rise of 29%.

FY27 saw solid growth for the business, despite the headwind of US tariffs. Revenue rose 6.7% to $1.81 billion, underlying operating profit (EBITDA) grew 4.5% to $284.1 million, and net profit after tax (NPAT) rose 1.7% to $138.1 million. This allowed the business to fund a 2.7% rise in the annual dividend per share to 38 cents.

Pleasingly, the company delivered double-digit revenue growth in coffee and cooking. Its young markets of China, South Korea, Mexico and Middle East) collectively grew revenue by more than 70%.

To manage exposure to US tariffs on China, it has substantially diversified its manufacturing. More than 85% of its 120-volt product gross profit dollars have now been sourced outside China.

It described the outlook for demand across its markets as “resilient” due to premium consumers, as the company navigates macroeconomic headwinds and company-specific tailwinds, including new product launches, fast-growing new geographies, solution plays and continued store-in-store expansion.

Charter Hall Group (ASX: CHC)

Charter Hall describes itself as a leading fully integrated diversified property investment and funds management group.

The ASX share invests in a diverse portfolio of high-quality properties across core sectors of office, industrial, logistics, retail and social infrastructure.

According to CMC Invest, there have been eight analyst ratings on the business within the last three months. Six of them were a buy rating and two of them were hold.

The average price target of those eight analysts is $25.15, which implies a possible rise of 32% over the next year. The most optimistic price target is $31.07 suggests a possible rise of 63%.

Charter Hall reported in FY26 that group funds under management (FUM) grew by $10 billion over the year to $94.3 billion, which is a strong driver of earnings. FY26 operating earnings per security (OEPS) grew 26.8% to $1.032.

The ASX share is expected to grow its OEPS by 10.5% in FY27 to $1.14, with the distribution expected to grow by another 6%.

The post 2 ASX shares highly recommended to buy: Experts appeared first on The Motley Fool Australia.

More reading

• Where I’d invest $15,000 in ASX shares now
• 40 ASX shares with ex-dividend dates next week
• How to build an ASX portfolio you can stick with for 10 years
• The five worst-performing ASX 200 shares in August unmasked
• 3 ASX growth shares to buy in September

Motley Fool contributor Tristan Harrison has positions in Breville Group. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

For years, ASX healthcare shares have been the market’s rotten apple. Once viewed as a defensive safe haven, the sector became one of the ASX’s biggest laggards.

The S&P/ASX 200 Health Care Index (ASX: XHJ) is still down 33% over five years and 18% over the past 12 months. Between January 2025 and June 2026, the index lost more than half its value.

Then August happened. The ASX 200 Health Care index surged 13% over a month and now sits 44% above its June low, comfortably beating the S&P/ASX 200 Index (ASX: XJO), which gained 3% over the same period.

So, have ASX healthcare shares finally turned the corner?

CSL leads the charge

The sector entered August with expectations firmly beaten down. That proved to be a blessing.

Companies largely cleared the low bar, with cost control doing much of the heavy lifting. Healthcare was also the only sector where more companies upgraded their outlooks for the year ahead than downgraded them.

CSL Ltd (ASX: CSL) was the standout. Its shares jumped 40% in August after plasma product sales for the June half came in ahead of expectations.

More importantly, management pointed to improving gross margins at CSL Behring, the plasma business that has caused plenty of headaches in recent years. UBS now believes the worst could be behind CSL ahead of its CEO transition in 2027.

Other healthcare heavyweights also delivered. Ansell Ltd (ASX: ANN) jumped 23% after beating expectations, with its FY27 guidance implying double-digit earnings-per-share growth at the midpoint.

Ramsay Health Care Ltd (ASX: RHC) gained 16% after a better-than-expected FY26 result. Its new management team expects further margin expansion in FY27, helped by more predictable private health insurance agreements, better operating theatre utilisation and procurement savings.

The rally wasn’t limited to those three names. Eight of the sector’s 10 largest ASX healthcare shares finished August higher. Cochlear Ltd (ASX: COH) climbed 13%, Telix Pharmaceuticals Ltd (ASX: TLX) rose 10%, and ResMed Inc (ASX: RMD) gained close to 10%.

Can the rebound continue?

This is where things get interesting. August was impressive, but FY27 will be the real test.

Management teams are generally optimistic, yet analysts aren’t quite as convinced. According to a recent Macquarie note, consensus FY27 earnings forecasts for the sector were actually cut by more than 2% during August.

There’s another problem: valuations have rebounded alongside share prices. The bargain-basement appeal that existed at June’s lows has largely disappeared. Investors are now paying more for the turnaround they hope is coming.

The August reporting season suggests CSL and several of its peers may finally be back on firmer ground. But after such a powerful rebound, the easy part may already be over.

Now, ASX healthcare shares need to deliver.

The post CSL led the ASX healthcare shares rebound. Can it continue? appeared first on The Motley Fool Australia.

More reading

• 4 high conviction ASX stock picks from Canaccord Genuity
• These ASX shares benefit from a high Aussie dollar
• What Warren Buffett’s investing style can teach superannuation investors
• CSL shares are up 94% from their low. What are brokers forecasting next?
• Looking to bank the upcoming CSL dividend? You better hurry!

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Cochlear, ResMed, and Telix Pharmaceuticals. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended Ansell, CSL, Cochlear, and Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Recently, investors have been searching for the optimal strategy to gain exposure to the artificial intelligence buildout. 

This has evolved from direct exposure through AI companies to the infrastructure that supports AI rather than in AI software itself.

The AI revolution and the ASX 

Because Australia has relatively few direct AI leaders comparable to Nvidia Corp (NASDAQ: NVDA) or Microsoft Corp (NASDAQ: MSFT), investors have focused on:

• Data-centre operators
• Electricity generators and infrastructure companies
• Mining companies with exposure to commodities needed to build and power data centres, particularly copper and uranium. 

ASX investors have also turned to thematic ASX ETFs that target these companies. 

Overall, the ASX AI investment strategy has increasingly become a “picks and shovels” approach: rather than trying to identify Australia’s next major AI software company, investors are targeting the physical infrastructure and resources needed to power and expand the global AI boom.

Adrad Holdings Ltd (ASX: AHL) has been identified as a potential beneficiary of the AI boom.

Company overview

Adrad is an Australian-based business specialising in the design, manufacture, importation and distribution of heat transfer solutions for the automotive and industrial markets in Australia, New Zealand and Southeast Asia.

Its stock price has risen over 50% year to date. 

Its strong rise in 2026 is closely connected to AI/data-centre infrastructure, but there is more to the story. AHL has exposure to the growing need for cooling systems for data centres, as well as mining, power generation and other heavy-industry applications.

Big upside for this ASX stock 

A fresh report from the team at Bell Potter suggests this ASX stock could be a long-term beneficiary of the AI boom. 

Bell Potter is increasingly positive on Adrad because of its exposure to the rapidly growing data-centre and AI infrastructure market. 

The company has responded to growing demand by doubling its Australian data-centre capacity and expanding manufacturing in Thailand, with the additional capacity already generating new customer orders. 

Bell Potter therefore expects this data-centre investment to support Adrad’s revenue and earnings growth over the medium term. 

While its FY27 forecasts remain unchanged, Bell Potter has upgraded its FY28 and FY29 expectations, increasing revenue forecasts by 3% and 5% and EPS forecasts by 9% and 13%, respectively. 

It now expects mid-to-high single-digit revenue growth and mid-to-high teens EPS growth in FY28 and FY29, respectively.

The broker has a buy recommendation on this ASX stock as well as an upgraded price target of $1.80 (previously $1.40). 

From yesterday’s closing price, this indicates approximately 14% upside. 

The post This ASX stock could be a surprise winner of the AI boom appeared first on The Motley Fool Australia.

More reading

• These are the 10 richest people in the world in September
• ASX shares investors are getting younger and trading more often: CBA report
• Want to invest in AI shares? Here’s how to do it on the ASX
• Are these 3 top Betashares ETFs a buy in September?
• Are these 2 top Vanguard ETFs still worth buying today?

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Microsoft and Nvidia. The Motley Fool Australia has recommended Microsoft and Nvidia. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.